This novel compound is believed to show improved anti-cancer effects in a compound humanized mouse model of pancreatic cancer. This discovery is published in Nature Communications.
Pancreatic cancer is the second-most common cancer in the world following glioblastoma (in women and men) – the aggressive form of the disease. In India about 490000 new cases of this very aggressive majority type of malignant cells are diagnosed and approximately 1500 new deaths in the country each year. Less than 10 years from the discovery of Therapy Vivifluous (TB) and its active compound TBK7 a PARP inhibitor for myelodysplastic syndromes (MDS) is planned.
Having identified this compound as well as TBK7 and TBK9 as effective against pancreatic cancer we present it along with TBK7 as potential drug candidates which are under development for epilepsy. This compound is found in the blood of mice carrying humanized pancreatic cancer genes. To treat the disease thought to be triggered by BRCA12 mutations TBK7 drug candidate has been developed into a therapeutic agent. However TBK7 does not work as well as our other drug candidates. Based on our studies we determined that this compound has potential to replace BRCA12 inhibitors in pancreatic cancer treated with experimental drugs.
S. K. Chandrasekaran NC-2 Department of Chemical Biology Clayton Foundation Professor of Chemical Biophysics and the senior author of this study says Our study shows that over the last three years our research team has used Humanized Double-idobacteria (HDIB) – a novel method for isolating genetically engineered bacteria – to extract unique compounds with excellent promise to enable our compound candidates to replace BRCA delivery inhibitors. The fact that TBK7 is present in larger amounts than TBK7 found in TBK7TBK9 inhibitors is a vital factor in the selection process of possible candidate compounds and the development of viable drug candidates to replace BRCA-targeting drugs.